News & Insights

RxC actively researches and publishes its point of view on key issues impacting the pharma and biotech industries.  We welcome your input on our pieces.  To be notified when we publish something new, please sign up for our updates newsletter.

Subscribe to Our Updates


LCM Stages.jpg

Driving Innovation of BioPharma Products through Life Cycle Planning

In this article RxC International reviews the types life cycle strategies and their duration of impact can vary significantly depending on what stage the product is in.   Five 'best practices' to help ensure practical, targeted and successful life cycle planning are introduced.


RxC International Gene Therapy March Newsletter Header Image.png

Monthly Gene Therapy Business Review - March 2018

Highlights and developments include: 

  1. First Reports of Luxturna Being Administered

  2. Gene Therapy Safety, Efficacy, and Science Still Evolving

  3. Targeted Delivery Continues to Expand: Topical Gene Therapy IND Application Filed

  4. Gene Therapy Targeted to NASH, Leveraging New Regeneron/Alnylam Partnership

  5. Gene Therapy May Heal Brain


RxC International Transforms Biopharmaceutical Life Cycle Management Planning with RxC ProLOGS™ Solution

RxC International announced today the launch of its RxC ProLOGS™ pharmaceutical life cycle management planning solution.  RxC ProLOGS incorporates in-depth market research, innovative concept development, advanced analytics, cross-functional client input, and industry best practices to produce actionable insights for maximizing product value.


Monthly Gene Therapy Business Review - February 2018

Top Stories for February 2018:

  1. Lessons Learned from Hepatitis C: Intense Competition Requires Careful Commercial Planning for Sickle Cell Gene Therapies

  2. Gene Therapy IP, Manufacturing, and Delivery Pathways Still Evolving

  3. FDA Moving Forward with its Role in Advancing a Modern Framework for Gene Therapy

Read about these developments and our commercial insights into the ongoing evolution of the gene therapy market.


Monthly Gene Therapy Business Review - January 2018

This month, the most noteworthy gene therapy stories include:

  • Still Learning What We Don’t Know: Gene Therapy Market Impacted by Safety Concerns

  • Headline “Gene Therapy Could Make Cancer Care More Unequal” Probably Not True

  • China’s Quest for Gene Therapy Success

  • Answering ICER: Spark CEO Offers Rationale for Luxturna Price


A little earlier than expected, Spark’s announces Luxturna pricing, $850k

RxC International has evaluated the Luxturna clinical story and its market opportunity, including critical questions regarding this highly-watched commercial launch.  Here's what you need to know.


Monthly Gene Therapy Business Review - December 2017

Monthly Gene Therapy Business Review - December 2017

This month, the most noteworthy gene therapy stories include:

  • First Mover Advantage? Gilead Blazes Trail for Competition

  • Newly-Published Yescarta Study Raises Safety Concerns

  • Results from Hemophilia Gene Therapy Studies Prompt Pricing Questions...Again

Read about these developments and our commercial insights into the ongoing evolution of the gene therapy market.


Monthly Gene Therapy Business Review - November 2017

November saw some important moments in gene therapy.  We have summarized the most noteworthy and included the remaining in our news and updates sections.


SlideShare: Avoiding the Most Common  Challenges Faced by Existing Pharma Co-Promotions

Existing pharma co-promotions face challenges that can threaten their success and longevity if not addressed. Learn about the these challenges and methods our expert co-promotion team has applied to remedy them.


RxC International Gene Therapy Newsletter

Landmark Month Sees Second Gene Therapy Approved and Other Wins

October was a landmark month for gene therapies with the approval of the second-ever gene therapy in the US, Yescarta (axicabtagene ciloleucel) from Kite and Gilead.  The prior approval of Novartis’ Kymriah is more proof that gene therapies are set to shake up the pharma industry.  Gene therapies saw other wins as Luxturna, Spark’s treatment for Leber congenital amaurosis, received the FDA’s recommendation for approval and Bluebird Bio’s interim data report for its gene therapy Lenti-D to treat cerebral adrenoleukodystrophy showed promising results.


RxC International Product Lifecycle Management Planning

Effective Pharmaceutical Life Cycle Management Planning: Optimizing Product Value over a Drug's Lifespan

Developing an effective drug life cycle management plan is critical for maximizing the value of a pharma product over the course of its commercial lifespan. Drawing from our deep expertise of pharmaceutical product lifecycle management, RxC International has identified key success factors and industry best practices as well as common pitfalls to avoid when developing and implementing LCM plans.


Partnering for Successful Life Cycle Management: 5 Reasons to Seek Outside Help

Pharmaceutical companies with effective Life Cycle Management (LCM) planning typically work with outside partners to develop and execute LCM plans.  Working with a third-party partner adds outside thinking and best practices to an organization.  “When you can [bring] in the experience that you need, you’ll benefit from the hard work that others have done, shorten your time to market for new products, and introduce new talent to your company,” writes Madeline Bennett of The Telegraph.